WebAug 3, 2024 · Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. WebMay 31, 2024 · Checkmate's lead investigational candidate, vidutolimod, is an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle (VLP) and has demonstrated clinical responses as a monotherapy in patients with PD-1 refractory melanoma.
Solid tumor biotech Checkmate Pharmaceuticals sets terms for $75 ... - IPOs
WebSep 9, 2024 · Total gross proceeds raised by Checkmate in IPO of $86.25 million Intention to use part of the net proceeds from the IPO to fund the development of its product candidate CMP-001, an asset Checkmate... December 19, 2024 WebAug 6, 2024 · Checkmate Pharmaceuticals, Inc. has completed an IPO in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,000,000 PriceRange: $15 Discount... February 13, 2024 i dreamt death came the other night
Checkmate Pharmaceuticals LinkedIn
WebAug 3, 2024 · C heckmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise... WebIpoPro - Renaissance Capital The data you are trying to access is only available to IPO Intelligence users . IPO Pro - "The Ultimate Resource for IPOs" Don't risk buying another … WebCheckmate Pharmaceuticals has raised a total of $170M in funding over 5 rounds. Their latest funding was raised on Jun 10, 2024 from a Series C round. Checkmate … is selenium free for commercial use